News | Stroke | October 12, 2023

Philips and World Stroke Organization Partner to Improve Access to High-quality Stroke Care

Two-year partnership focused on advocacy, education, and raising awareness of stroke as a global healthcare challenge

Two-year partnership focused on advocacy, education, and raising awareness of stroke as a global healthcare challenge

Getty Images


October 12, 2023 — Royal Philips, a global leader in health technology, and the World Stroke Organization (WSO), the world’s only global non-governmental organization focused on stroke, today announced the signing of a two-year partnership aimed at improving access to high-quality stroke care. Building on their shared commitment to delivering improvements in stroke prevention, treatment, rehabilitation and support, Philips and WSO will leverage their respective strengths to elevate the public understanding of stroke as a global health issue, starting with joint initiatives on World Stroke Day 2023(October 29) to build greater public awareness, which is fundamental to improving stroke patient outcomes. They will also work together to support the implementation of innovative treatment methods with the potential to transform the stroke care pathway, where reducing the time between symptom onset and effective treatment is critical to improving patient outcomes. 

Announcing the partnership WSO President Prof Sheila Martins said, “WSO is committed to accelerating the global implementation of evidence-based treatment and care for stroke patients globally. We know what works and we know that it takes every part of the healthcare system, working together to bring quality care to every patient.” 

“Both innovation and public awareness are essential to improve time-to-treatment and access to care for patients suffering a stroke,” said Dr. Atul Gupta, Chief Medical Officer of Image Guided Therapy at Philips. “Working closely with WSO, we can further shape the future of neurovascular interventions and help provide groundbreaking and effective high-quality care to patients so they can resume normal life after a stroke.” 

Stroke is the second leading cause of death and the leading cause of disability worldwide, with around 12 million people experiencing a stroke each year, including 6.5 million people who die as a result. Those who do survive are often left with a complex range of communication, cognitive, physical, and emotional challenges for the rest of their life. To improve access to high-quality care that reduces the burden stroke places on individuals, and the financial and social impact it has on society, Philips and WSO will collaborate across a range of stroke-related areas. These include driving advocacy and policy based on the latest clinical research and treatment guidelines to inform government departments and healthcare providers about the latest developments in stroke treatment, and supporting community engagement. 

Philips is a recognized leader in solutions that support the rapid treatment of stroke to minimize its impact on patients, including solutions for stroke monitoring and communication in ambulances, tele-stroke patient assessment, artificial intelligence (AI) supporting diagnostic imaging and analysis, image-guided therapy, and neurological and cardiac monitoring and assessment. The company also offers fully integrated angio suite systems designed to facilitate a stroke procedure called mechanical thrombectomy. During a thrombectomy, a specialized medical device is used to physically remove or break up the clot, restoring blood flow to the affected part of the brain. This quality-of-life-saving procedure is often performed to minimize damage to brain tissue and improve the chances of a patient's recovery after a stroke. 

For more information: www.philips.com


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now